The contract amendment landed on a site director’s desk in late March, six weeks after FDA’s February 2026 announcement that a single adequate and well-controlled pivotal trial would become the default standard for marketing authorization. The amendment added two new secondary endpoints, restructured the enrollment window from 36 months to 22 months, and adjusted the per-patient payment schedule. What it did not include was any acknowledgment that the site had already hired a second coordinator for a two-trial timeline that no longer existed. The sponsor had reconfigured the entire development program. The site was catching up in real time.

That gap between sponsor strategy and site execution is exactly where the February 2026 shift creates its sharpest operational friction. FDA’s new default position, which formally moves away from the longstanding expectation of two independent Phase 3 studies, compresses every downstream timeline into a single trial that must carry the full evidentiary weight. For sites running CNS programs, where screen failure rates already run 40 to 60 percent on highly specific populations, that compression is not theoretical. Every delayed startup day now costs twice as much program risk as it did under a two-trial architecture.

One Trial to Carry Everything

The historical context matters here. The FDA’s longstanding “two-trial dogma” meant that a failed first Phase 3 could, in principle, be followed by a redesigned second attempt. Sponsors built their site activation networks accordingly, often staggering enrollment across geographic waves and maintaining reserve sites they could activate if a primary cohort fell short. That architecture absorbed startup delays and screen failure volatility across two trials. Under the single-trial default, those buffers evaporate. A site that needs 90 days to reach first-patient-in is not running behind. Under the new model, it is potentially costing the sponsor its only pivotal shot.

Lecanemab‘s path to traditional approval illustrates what the single-trial standard demands of site operations. The FDA’s traditional approval of lecanemab (Leqembi) on July 6, 2023, was supported by data from a single Phase 3 randomized controlled trial, CLARITY AD. That trial enrolled 1,795 participants across a narrowly defined early Alzheimer’s population, which required sites to execute amyloid confirmation via PET or CSF at screening, a procedure that adds cost, calendar time, and a meaningful screen failure rate. Sites that ran CLARITY AD know what that operational load looks like. Now consider that under the February 2026 framework, every CNS program targeting a biomarker-confirmed population will face that same intensity on a timeline where there is no second trial to absorb the enrollment shortfall.

The budget math gets uncomfortable quickly. Research from the Tufts Center for the Study of Drug Development found that a single protocol amendment in a typical Phase 3 trial adds an average of three months and $535,000 in direct costs. Under a two-trial paradigm, sponsors spread protocol learning across programs. Under the single-trial default, any mid-course amendment is a significant event, arriving at a site network that is already running at full enrollment pressure. Sites I work with are already seeing this in contract language: amendment clauses that previously triggered routine budget reconciliations are now structured with performance holdbacks tied to enrollment pace, because sponsors cannot afford to renegotiate scope while the clock is running on their only pivotal dataset.

Which raises an uncomfortable question for site qualification: are the sites being selected for these programs actually resourced for the execution load the new paradigm demands?

Phase 2 Rigor Is Now a Site Readiness Test

The single-trial default does not reduce the evidential burden. It concentrates it. Sponsors moving into a single Phase 3 need their Phase 2 data to carry far more weight than it historically did, and the FDA’s March 2024 revised draft guidance on Early Alzheimer’s Disease drug development makes clear that endpoint selection and biomarker validation in Phase 2 are prerequisites, not suggestions, for a credible Phase 3 submission. For site operations teams, that creates a new pressure point at Phase 2 close-out: the quality of data coming off a 60-patient Phase 2 cohort is now a direct input into whether a sponsor will invest in a full single-trial Phase 3 at those same sites.

Sites that treated Phase 2 as a lower-scrutiny environment, acceptable protocol deviation counts, informal source documentation practices, coordinator-managed query resolution without PI sign-off, are now discovering that sponsor monitoring teams are applying near-Phase 3 oversight standards to the earlier study. ICH E6(R3), formally adopted by the FDA on September 8, 2025, incorporates risk-based monitoring frameworks that make it operationally straightforward for sponsors to deploy intensive remote oversight across both phases without additional budget authorization. The sites that built documentation discipline into Phase 2, ALCOA-C-compliant source records, TMF completeness above 95 percent at interim milestones, PI-level protocol deviation review within 48 hours, are the sites getting the Phase 3 activation calls.

The sites that did not are getting scored out of networks they expected to stay in.

What Changes Monday Morning

For site operations leads, the practical adjustment is a pre-activation feasibility reconciliation that specifically addresses single-trial load. Before signing any Phase 3 CNS contract in 2026, the site needs an explicit enrollment rate model that accounts for biomarker screening attrition, calculates the coordinator hours per screened patient (not per enrolled patient), and identifies the calendar point at which the site will need to add staffing. Sponsors are not volunteering this math. Sites need to run it themselves, because a contract structured for 80 enrolled patients in 18 months looks very different at month nine when screen failure rates are running at 55 percent and the enrollment window cannot move.

For sponsor-side clinical operations and CTMs, the immediate shift is reclassifying site startup latency as a program-level risk rather than a site-level performance issue. Under the two-trial model, a site that missed its first-patient-in target by 45 days was a local problem with local consequences. Under the single-trial default, the same delay compresses the enrollment window for an entire program that has no statistical safety net. That means pre-SIV readiness assessments need teeth: not a checklist, but a resource audit that confirms the coordinator-to-protocol ratio, confirms pharmacy activation status, and confirms IRB-approved consent version alignment before the monitoring clock starts running.

The February 2026 shift was framed as a regulatory efficiency gain. Operationally, it transferred risk from the sponsor’s development portfolio directly onto the sites running the single trial that now has to be right the first time. The sites that understand that transfer, and price their contracts accordingly, will be the ones sponsors cannot afford to lose.

References

  1. medRxiv Neurology — “Positioning Early Phase CNS Trials for Regulatory and Investor Success: Strategic Implications of the Single Phase 3 Approval Paradigm”
  2. Becaris Publishing — “FDA Sets One Pivotal Trial as New Default Standard for Regulatory Approvals”
  3. ProPharma Group — “FDA Default Drug Approval Requirements: One Pivotal Trial — Regulatory Strategy Implications”
  4. Alzheimers.gov — “FDA Grants Traditional Approval for Leqembi (Lecanemab), July 6, 2023”
  5. Applied Clinical Trials — “Acknowledging Cycle Time Impact of Protocol Amendments” (Tufts CSDD data)
  6. Clinical Trials Arena — “FDA to Allow One Pivotal Trial Instead of Two for Drug Approval”
  7. FDA — “Early Alzheimer’s Disease: Developing Drugs for Treatment,” revised draft guidance, March 11, 2024
  8. FDA — “E6(R3) Good Clinical Practice (GCP)” guidance, adopted September 8, 2025
+ posts